^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Excerpt:
...Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)...Biomarker response was defined as a > 20% decrease in the biomarker AFP from baseline during 8 weeks of treatment. Data presented is median overall survival of those participants who achieved the defined biomarker response. Participants enrolled in Part A had a baseline AFP level of >1.5 upper limit normal (ULN). Participants enrolled in Part B had baseline AFP level <1.5 ULN...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A Phase 2 Study of Galunisertib (TGF-ß1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Published date:
07/01/2019
Excerpt:
Patients with baseline AFP ≥ 400 ng/mL or patients with baseline TGF-β1 ≥ baseline median (1956 pg/mL) demonstrated trends toward longer TTP.
DOI:
10.14309/ctg.0000000000000056
Trial ID: